| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Surgical Procedures | 30 | 2022 | 171 | 11.070 |
Why?
|
| Thrombelastography | 35 | 2022 | 46 | 8.650 |
Why?
|
| Blood Coagulation | 27 | 2021 | 116 | 6.550 |
Why?
|
| Cardiopulmonary Bypass | 16 | 2021 | 40 | 4.940 |
Why?
|
| Blood Coagulation Disorders | 11 | 2022 | 25 | 4.940 |
Why?
|
| Anticoagulants | 24 | 2022 | 293 | 4.890 |
Why?
|
| Blood Coagulation Factors | 14 | 2021 | 31 | 4.340 |
Why?
|
| Thrombin | 18 | 2019 | 68 | 4.330 |
Why?
|
| Hemostasis | 21 | 2022 | 47 | 4.130 |
Why?
|
| Factor VIIa | 13 | 2019 | 29 | 4.070 |
Why?
|
| Blood Transfusion | 15 | 2022 | 73 | 3.960 |
Why?
|
| Hemostatics | 12 | 2022 | 18 | 3.730 |
Why?
|
| Postoperative Hemorrhage | 11 | 2019 | 30 | 3.570 |
Why?
|
| Fibrinogen | 12 | 2020 | 50 | 3.550 |
Why?
|
| Thrombosis | 8 | 2021 | 147 | 3.260 |
Why?
|
| Hemophilia A | 5 | 2021 | 15 | 3.130 |
Why?
|
| Heparin | 16 | 2022 | 110 | 3.080 |
Why?
|
| Antifibrinolytic Agents | 6 | 2021 | 22 | 2.600 |
Why?
|
| Blood Coagulation Tests | 13 | 2021 | 27 | 2.570 |
Why?
|
| Antithrombins | 10 | 2020 | 28 | 2.570 |
Why?
|
| Humans | 103 | 2023 | 26856 | 2.550 |
Why?
|
| Liver Transplantation | 6 | 2018 | 51 | 2.450 |
Why?
|
| Perioperative Care | 8 | 2020 | 35 | 2.440 |
Why?
|
| Warfarin | 9 | 2017 | 94 | 2.230 |
Why?
|
| Blood Component Transfusion | 5 | 2021 | 13 | 2.050 |
Why?
|
| Hemodilution | 7 | 2019 | 9 | 1.990 |
Why?
|
| Blood Loss, Surgical | 9 | 2019 | 52 | 1.980 |
Why?
|
| Thrombocytopenia | 6 | 2022 | 113 | 1.870 |
Why?
|
| Coagulants | 5 | 2019 | 7 | 1.700 |
Why?
|
| Plasma | 12 | 2022 | 32 | 1.690 |
Why?
|
| Intraoperative Care | 4 | 2021 | 22 | 1.670 |
Why?
|
| Recombinant Proteins | 16 | 2019 | 408 | 1.660 |
Why?
|
| Prothrombin Time | 9 | 2017 | 21 | 1.560 |
Why?
|
| Wounds and Injuries | 6 | 2022 | 168 | 1.520 |
Why?
|
| Protamines | 4 | 2019 | 11 | 1.470 |
Why?
|
| Jehovah's Witnesses | 3 | 2018 | 5 | 1.440 |
Why?
|
| Venous Thromboembolism | 2 | 2023 | 132 | 1.440 |
Why?
|
| Operative Blood Salvage | 2 | 2021 | 3 | 1.400 |
Why?
|
| Hemorrhage | 8 | 2021 | 259 | 1.310 |
Why?
|
| Point-of-Care Systems | 7 | 2020 | 20 | 1.300 |
Why?
|
| Tranexamic Acid | 3 | 2021 | 13 | 1.250 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2020 | 30 | 1.220 |
Why?
|
| Hemostatic Techniques | 4 | 2018 | 14 | 1.120 |
Why?
|
| Middle Aged | 28 | 2021 | 6825 | 1.110 |
Why?
|
| Fibrinolysis | 4 | 2019 | 21 | 1.100 |
Why?
|
| Complement C1 Inhibitor Protein | 2 | 2023 | 3 | 1.070 |
Why?
|
| Male | 36 | 2021 | 12866 | 1.060 |
Why?
|
| Aged | 22 | 2021 | 5169 | 1.050 |
Why?
|
| Fibrin | 4 | 2017 | 17 | 1.040 |
Why?
|
| Platelet Count | 10 | 2021 | 112 | 1.010 |
Why?
|
| Shock, Septic | 3 | 2020 | 38 | 1.000 |
Why?
|
| Platelet Aggregation Inhibitors | 7 | 2019 | 187 | 0.980 |
Why?
|
| Factor VIII | 6 | 2021 | 19 | 0.970 |
Why?
|
| Vasodilation | 3 | 2020 | 114 | 0.960 |
Why?
|
| Blood Platelets | 9 | 2019 | 203 | 0.960 |
Why?
|
| Factor X | 3 | 2019 | 11 | 0.950 |
Why?
|
| Erythrocytes | 5 | 2020 | 84 | 0.950 |
Why?
|
| Hirudins | 3 | 2017 | 17 | 0.940 |
Why?
|
| Hematocrit | 5 | 2021 | 26 | 0.940 |
Why?
|
| Platelet Aggregation | 3 | 2019 | 43 | 0.920 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 4 | 2019 | 34 | 0.880 |
Why?
|
| Vasoconstrictor Agents | 3 | 2020 | 34 | 0.870 |
Why?
|
| Blood Pressure | 3 | 2022 | 351 | 0.850 |
Why?
|
| Female | 31 | 2021 | 14462 | 0.840 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 131 | 0.840 |
Why?
|
| Retrospective Studies | 13 | 2021 | 2444 | 0.800 |
Why?
|
| Factor V Deficiency | 1 | 2022 | 4 | 0.790 |
Why?
|
| Antithrombin III Deficiency | 1 | 2021 | 6 | 0.790 |
Why?
|
| Hemophilia B | 1 | 2021 | 3 | 0.790 |
Why?
|
| Antibodies, Bispecific | 1 | 2021 | 7 | 0.780 |
Why?
|
| Factor IX | 1 | 2021 | 4 | 0.780 |
Why?
|
| Peptide Fragments | 2 | 2017 | 197 | 0.770 |
Why?
|
| Aneurysm, Dissecting | 3 | 2016 | 12 | 0.730 |
Why?
|
| Angioedemas, Hereditary | 1 | 2020 | 1 | 0.720 |
Why?
|
| Time Factors | 13 | 2019 | 1564 | 0.710 |
Why?
|
| Dabigatran | 2 | 2020 | 20 | 0.700 |
Why?
|
| Shock | 1 | 2020 | 17 | 0.690 |
Why?
|
| Hemoglobins | 2 | 2018 | 116 | 0.690 |
Why?
|
| Transfusion Reaction | 4 | 2019 | 10 | 0.690 |
Why?
|
| Heparin Antagonists | 2 | 2010 | 3 | 0.690 |
Why?
|
| Adult | 22 | 2021 | 7389 | 0.680 |
Why?
|
| Pain | 1 | 2022 | 252 | 0.670 |
Why?
|
| Aortic Aneurysm | 3 | 2016 | 15 | 0.660 |
Why?
|
| Mammary Arteries | 1 | 2019 | 6 | 0.660 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2019 | 2 | 0.660 |
Why?
|
| Propofol | 1 | 2019 | 10 | 0.660 |
Why?
|
| Prospective Studies | 9 | 2021 | 1219 | 0.660 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 2 | 2010 | 3 | 0.660 |
Why?
|
| Hypertension | 1 | 2022 | 304 | 0.660 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2019 | 8 | 0.650 |
Why?
|
| Ultrasonic Waves | 1 | 2019 | 3 | 0.650 |
Why?
|
| End Stage Liver Disease | 2 | 2016 | 9 | 0.640 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 68 | 0.640 |
Why?
|
| Bloodless Medical and Surgical Procedures | 1 | 2018 | 1 | 0.640 |
Why?
|
| Aorta | 3 | 2016 | 123 | 0.630 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2019 | 34 | 0.630 |
Why?
|
| Pulmonary Valve | 1 | 2018 | 14 | 0.620 |
Why?
|
| Tetralogy of Fallot | 1 | 2018 | 22 | 0.620 |
Why?
|
| Coronary Artery Bypass | 1 | 2019 | 66 | 0.620 |
Why?
|
| Anemia | 1 | 2018 | 41 | 0.620 |
Why?
|
| Epoprostenol | 1 | 2017 | 1 | 0.600 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2018 | 63 | 0.600 |
Why?
|
| Pipecolic Acids | 2 | 2010 | 2 | 0.590 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 73 | 0.590 |
Why?
|
| Erythrocyte Count | 1 | 2017 | 5 | 0.580 |
Why?
|
| Heart Diseases | 1 | 2018 | 68 | 0.580 |
Why?
|
| Postoperative Complications | 3 | 2021 | 605 | 0.580 |
Why?
|
| International Normalized Ratio | 7 | 2017 | 27 | 0.570 |
Why?
|
| Polymerization | 1 | 2017 | 14 | 0.560 |
Why?
|
| Lung Transplantation | 1 | 2017 | 4 | 0.560 |
Why?
|
| Hemostasis, Surgical | 2 | 2013 | 7 | 0.550 |
Why?
|
| Algorithms | 5 | 2021 | 419 | 0.550 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 47 | 0.550 |
Why?
|
| Pulmonary Embolism | 1 | 2018 | 126 | 0.550 |
Why?
|
| Partial Thromboplastin Time | 4 | 2011 | 18 | 0.550 |
Why?
|
| Platelet Transfusion | 5 | 2021 | 29 | 0.540 |
Why?
|
| Viscoelastic Substances | 1 | 2016 | 2 | 0.530 |
Why?
|
| Plasma Exchange | 1 | 2017 | 103 | 0.530 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 57 | 0.530 |
Why?
|
| Treatment Outcome | 12 | 2020 | 2267 | 0.510 |
Why?
|
| Afibrinogenemia | 2 | 2019 | 3 | 0.510 |
Why?
|
| Hematology | 2 | 2015 | 24 | 0.500 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2019 | 285 | 0.490 |
Why?
|
| Fibrinolytic Agents | 3 | 2013 | 67 | 0.480 |
Why?
|
| In Vitro Techniques | 8 | 2009 | 239 | 0.470 |
Why?
|
| Prothrombin | 3 | 2009 | 15 | 0.460 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2013 | 6 | 0.450 |
Why?
|
| Resuscitation | 3 | 2022 | 59 | 0.440 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2013 | 5 | 0.440 |
Why?
|
| Whole Blood Coagulation Time | 5 | 2020 | 6 | 0.440 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2012 | 588 | 0.430 |
Why?
|
| Aprotinin | 2 | 2010 | 2 | 0.410 |
Why?
|
| Cohort Studies | 5 | 2021 | 860 | 0.410 |
Why?
|
| Vitamin K | 2 | 2008 | 39 | 0.370 |
Why?
|
| Drug Monitoring | 3 | 2012 | 34 | 0.370 |
Why?
|
| Blood Viscosity | 2 | 2007 | 10 | 0.360 |
Why?
|
| Point-of-Care Testing | 2 | 2020 | 3 | 0.350 |
Why?
|
| Platelet Function Tests | 2 | 2020 | 24 | 0.340 |
Why?
|
| Factor IXa | 1 | 2009 | 1 | 0.330 |
Why?
|
| Angiotensin II | 2 | 2020 | 54 | 0.330 |
Why?
|
| Aptamers, Nucleotide | 1 | 2009 | 13 | 0.330 |
Why?
|
| Aminocaproic Acid | 2 | 2020 | 6 | 0.320 |
Why?
|
| Propensity Score | 2 | 2019 | 54 | 0.310 |
Why?
|
| Predictive Value of Tests | 6 | 2021 | 472 | 0.300 |
Why?
|
| Religion and Medicine | 1 | 2007 | 6 | 0.290 |
Why?
|
| Case-Control Studies | 2 | 2019 | 701 | 0.280 |
Why?
|
| Disease Management | 3 | 2020 | 84 | 0.280 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2007 | 84 | 0.260 |
Why?
|
| Drug Interactions | 3 | 2019 | 77 | 0.260 |
Why?
|
| Pilot Projects | 2 | 2021 | 391 | 0.250 |
Why?
|
| Risk Factors | 3 | 2020 | 2017 | 0.250 |
Why?
|
| Blood Cells | 1 | 2004 | 10 | 0.240 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 1394 | 0.240 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2020 | 36 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 358 | 0.230 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 203 | 0.230 |
Why?
|
| Kallikreins | 1 | 2004 | 4 | 0.230 |
Why?
|
| Erythrocyte Transfusion | 2 | 2021 | 15 | 0.230 |
Why?
|
| Thiophenes | 2 | 2013 | 14 | 0.220 |
Why?
|
| Oligopeptides | 1 | 2004 | 95 | 0.210 |
Why?
|
| Piperazines | 2 | 2013 | 45 | 0.210 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 61 | 0.210 |
Why?
|
| Monitoring, Intraoperative | 3 | 2018 | 30 | 0.210 |
Why?
|
| Endothelium, Vascular | 2 | 2020 | 305 | 0.210 |
Why?
|
| Peptides | 1 | 2004 | 280 | 0.200 |
Why?
|
| Factor V | 1 | 2022 | 14 | 0.200 |
Why?
|
| Fibrinolysin | 1 | 2021 | 15 | 0.200 |
Why?
|
| Elasticity | 2 | 2013 | 49 | 0.190 |
Why?
|
| Pain Threshold | 1 | 2022 | 89 | 0.190 |
Why?
|
| Shock, Hemorrhagic | 1 | 2021 | 47 | 0.190 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 53 | 0.180 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 79 | 0.180 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 6 | 0.180 |
Why?
|
| Vasopressins | 1 | 2020 | 4 | 0.180 |
Why?
|
| Coagulation Protein Disorders | 1 | 2020 | 1 | 0.180 |
Why?
|
| Intraoperative Period | 2 | 2018 | 21 | 0.170 |
Why?
|
| Hypotension | 1 | 2020 | 18 | 0.170 |
Why?
|
| Spine | 1 | 2021 | 60 | 0.170 |
Why?
|
| Kaolin | 3 | 2012 | 5 | 0.170 |
Why?
|
| Blood Preservation | 1 | 2020 | 9 | 0.170 |
Why?
|
| Data Interpretation, Statistical | 2 | 2010 | 56 | 0.170 |
Why?
|
| Adenosine Monophosphate | 1 | 2019 | 20 | 0.170 |
Why?
|
| Cell Membrane Permeability | 1 | 2020 | 42 | 0.170 |
Why?
|
| Reaction Time | 1 | 2020 | 94 | 0.170 |
Why?
|
| Potassium Channels | 1 | 2019 | 20 | 0.170 |
Why?
|
| Maryland | 1 | 2019 | 7 | 0.160 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2012 | 12 | 0.160 |
Why?
|
| Critical Illness | 1 | 2020 | 68 | 0.160 |
Why?
|
| Morbidity | 1 | 2019 | 57 | 0.160 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 41 | 0.160 |
Why?
|
| Vasoplegia | 1 | 2018 | 3 | 0.160 |
Why?
|
| Electrodes | 1 | 2019 | 71 | 0.160 |
Why?
|
| Postoperative Care | 1 | 2019 | 67 | 0.160 |
Why?
|
| Blood Substitutes | 1 | 2018 | 9 | 0.160 |
Why?
|
| Neurosurgical Procedures | 1 | 2021 | 216 | 0.160 |
Why?
|
| Hospital Mortality | 1 | 2019 | 148 | 0.150 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2017 | 22 | 0.150 |
Why?
|
| Transfusion Medicine | 1 | 2017 | 1 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 1 | 2017 | 30 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2017 | 10 | 0.150 |
Why?
|
| Reoperation | 1 | 2018 | 144 | 0.140 |
Why?
|
| Arginine | 2 | 2010 | 39 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2010 | 57 | 0.140 |
Why?
|
| Lung | 1 | 2020 | 346 | 0.140 |
Why?
|
| Sulfonamides | 2 | 2010 | 69 | 0.140 |
Why?
|
| Prasugrel Hydrochloride | 2 | 2013 | 18 | 0.140 |
Why?
|
| Quality of Life | 1 | 2020 | 463 | 0.140 |
Why?
|
| Animals | 4 | 2020 | 9954 | 0.140 |
Why?
|
| Registries | 1 | 2018 | 383 | 0.130 |
Why?
|
| Living Donors | 1 | 2016 | 3 | 0.130 |
Why?
|
| Heart Transplantation | 1 | 2016 | 42 | 0.130 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 84 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 98 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2016 | 228 | 0.130 |
Why?
|
| Inflammation | 1 | 2020 | 598 | 0.130 |
Why?
|
| Biomarkers | 3 | 2019 | 731 | 0.120 |
Why?
|
| Heart Failure | 1 | 2017 | 232 | 0.120 |
Why?
|
| Central Venous Catheters | 1 | 2014 | 6 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2016 | 221 | 0.120 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 42 | 0.120 |
Why?
|
| Viscosity | 1 | 2013 | 37 | 0.110 |
Why?
|
| Perfusion | 1 | 2013 | 43 | 0.110 |
Why?
|
| Blood Specimen Collection | 1 | 2013 | 14 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2014 | 282 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2020 | 1339 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2021 | 586 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 1927 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2013 | 231 | 0.110 |
Why?
|
| Georgia | 1 | 2012 | 21 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 206 | 0.100 |
Why?
|
| Aorta, Thoracic | 2 | 2010 | 49 | 0.100 |
Why?
|
| Drug Substitution | 1 | 2011 | 5 | 0.100 |
Why?
|
| Acute Lung Injury | 1 | 2011 | 12 | 0.100 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 748 | 0.100 |
Why?
|
| Blood Flow Velocity | 1 | 2011 | 63 | 0.100 |
Why?
|
| ROC Curve | 2 | 2021 | 137 | 0.090 |
Why?
|
| Blood Cell Count | 1 | 2010 | 15 | 0.090 |
Why?
|
| Fluid Therapy | 1 | 2010 | 14 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 80 | 0.090 |
Why?
|
| Pharmaceutic Aids | 1 | 2010 | 1 | 0.090 |
Why?
|
| Spleen | 1 | 2010 | 109 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 189 | 0.080 |
Why?
|
| Antidotes | 1 | 2009 | 2 | 0.080 |
Why?
|
| Injury Severity Score | 2 | 2020 | 117 | 0.080 |
Why?
|
| Thrombomodulin | 1 | 2009 | 10 | 0.080 |
Why?
|
| Swine | 1 | 2010 | 220 | 0.080 |
Why?
|
| Cytochalasins | 1 | 2009 | 1 | 0.080 |
Why?
|
| Oligonucleotides | 1 | 2009 | 27 | 0.080 |
Why?
|
| Protein C | 1 | 2009 | 38 | 0.080 |
Why?
|
| Drug Hypersensitivity | 1 | 2009 | 22 | 0.080 |
Why?
|
| Adenosine Diphosphate | 2 | 2005 | 27 | 0.080 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2005 | 20 | 0.080 |
Why?
|
| Homeostasis | 1 | 2009 | 113 | 0.080 |
Why?
|
| Kinetics | 1 | 2009 | 538 | 0.070 |
Why?
|
| Aortic Valve Prolapse | 1 | 2007 | 1 | 0.070 |
Why?
|
| Tunica Intima | 1 | 2007 | 9 | 0.070 |
Why?
|
| Thromboembolism | 1 | 2007 | 57 | 0.070 |
Why?
|
| Aortic Rupture | 1 | 2007 | 8 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 1 | 2007 | 46 | 0.070 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2007 | 21 | 0.070 |
Why?
|
| Models, Animal | 1 | 2007 | 128 | 0.070 |
Why?
|
| Informed Consent | 1 | 2007 | 23 | 0.070 |
Why?
|
| Antibodies | 1 | 2007 | 124 | 0.070 |
Why?
|
| Aortic Valve | 1 | 2007 | 90 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2005 | 316 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 110 | 0.060 |
Why?
|
| Young Adult | 3 | 2019 | 2584 | 0.060 |
Why?
|
| Clot Retraction | 1 | 2005 | 1 | 0.060 |
Why?
|
| Batroxobin | 1 | 2004 | 1 | 0.060 |
Why?
|
| Pseudopodia | 1 | 2004 | 7 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 29 | 0.060 |
Why?
|
| Aortic Diseases | 1 | 2004 | 16 | 0.060 |
Why?
|
| Premedication | 1 | 2004 | 5 | 0.060 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2004 | 73 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2004 | 100 | 0.060 |
Why?
|
| Echocardiography | 1 | 2004 | 107 | 0.060 |
Why?
|
| Ticlopidine | 1 | 2004 | 34 | 0.060 |
Why?
|
| Rats | 1 | 2007 | 1536 | 0.060 |
Why?
|
| Nicardipine | 1 | 2003 | 1 | 0.050 |
Why?
|
| Fenoldopam | 1 | 2003 | 1 | 0.050 |
Why?
|
| Umbilical Arteries | 1 | 2003 | 2 | 0.050 |
Why?
|
| Hydralazine | 1 | 2003 | 6 | 0.050 |
Why?
|
| Nitroglycerin | 1 | 2003 | 27 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2003 | 79 | 0.050 |
Why?
|
| Trauma Severity Indices | 1 | 2021 | 37 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2022 | 70 | 0.050 |
Why?
|
| United States | 1 | 2007 | 2035 | 0.050 |
Why?
|
| Trauma Centers | 1 | 2021 | 115 | 0.050 |
Why?
|
| Catecholamines | 1 | 2020 | 18 | 0.040 |
Why?
|
| Blood Component Removal | 1 | 2020 | 3 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 67 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 193 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2019 | 32 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 94 | 0.040 |
Why?
|
| Patient Selection | 1 | 2019 | 143 | 0.040 |
Why?
|
| Streptococcus anginosus | 1 | 2018 | 1 | 0.040 |
Why?
|
| Intestinal Perforation | 1 | 2018 | 13 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 509 | 0.040 |
Why?
|
| Escherichia coli Infections | 1 | 2018 | 44 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 2018 | 34 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2018 | 328 | 0.030 |
Why?
|
| Patients | 1 | 2015 | 17 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 43 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 68 | 0.030 |
Why?
|
| Reference Values | 1 | 2015 | 198 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2016 | 848 | 0.030 |
Why?
|
| Diatomaceous Earth | 1 | 2012 | 2 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2007 | 12 | 0.020 |
Why?
|
| Replantation | 1 | 2007 | 7 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2007 | 9 | 0.020 |
Why?
|
| Sinus of Valsalva | 1 | 2007 | 12 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2007 | 43 | 0.020 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2007 | 36 | 0.020 |
Why?
|
| Acute Disease | 1 | 2007 | 156 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2007 | 127 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 233 | 0.020 |
Why?
|
| Calcium Chloride | 1 | 2005 | 6 | 0.020 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2005 | 15 | 0.020 |
Why?
|
| Observer Variation | 1 | 2004 | 43 | 0.020 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 2003 | 3 | 0.010 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2003 | 4 | 0.010 |
Why?
|
| Potassium Chloride | 1 | 2003 | 10 | 0.010 |
Why?
|
| Thromboxane A2 | 1 | 2003 | 5 | 0.010 |
Why?
|
| Dopamine | 1 | 2003 | 21 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 447 | 0.010 |
Why?
|
| Pre-Eclampsia | 1 | 2003 | 48 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2003 | 162 | 0.010 |
Why?
|
| Pregnancy | 1 | 2003 | 1130 | 0.010 |
Why?
|